Traveler's Diarrhea - Market Insights, Epidemiology and Market Forecast-2028
DelveInsight’s ‘Traveler's Diarrhea - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Traveler’s Diarrhea (TD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Traveler’s Diarrhea (CCA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2028
Traveler’s Diarrhea (TD) - Disease Understanding
Traveler's diarrhea (TD) is defined as ≥3 unformed stools in 24 hours accompanied by at least 1 of the following: fever, nausea, vomiting, cramps, tenesmus, or bloody stools (dysentery), in a traveler from a developed country visiting a less developed country. It is usually a benign self-limited illness lasting 3 to 5 days (mean 3.6 days).
Classic travelers’ diarrhea is defined as at least three loose to watery stools in 24 hours with or without one or more symptoms of abdominal cramps, fever, nausea, vomiting, or blood in the stool. Mild to moderate diarrhea is one or two loose stools in 24 hours with or without another enteric symptom. The median time to onset is six or seven days after arrival. Although the diarrhea often resolves spontaneously over three or four days, up to a quarter of affected travelers need to alter their plans, interrupting their holiday or business activities.
TD is a clinical syndrome that can result from a variety of intestinal pathogens. Bacterial pathogens are the predominant risk, thought to account for up to 80%–90% of TD. Intestinal viruses usually account for at least 5%–8% of illnesses, although improved diagnostics may increase recognition of norovirus infections in the future. Infections with protozoal pathogens are slower to manifest symptoms and collectively account for approximately 10% of diagnoses in longer-term travelers.
Traveler’s Diarrhea (TD) Epidemiology
The Traveler’s Diarrhea (TD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Traveler’s Diarrhea (TD) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Traveler’s Diarrhea (TD) Epidemiology Segmentation
The disease epidemiology covered in the report is segmented by total incident population, diagnosed population and severity-specific incident population of Traveler’s Diarrhea.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of Traveler’s Diarrhea (TD) was estimated to be 41,611,405 [7MM] in 2018. United States accounts for the highest TD cases (16,964,730 in 2018), followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Traveler’s Diarrhea, followed by Italy.
Traveler’s Diarrhea (TD) Drug Chapters
This segment of the Traveler’s Diarrhea (TD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The treatment therapies comprise of oral hydration and diet modification strategy followed by Anti-motility drugs or antidiarrheal drugs (also known as symptomatic therapy) and Antibiotics/Antimicrobials. The first step is Oral Hydration that involves replenishment of fluids and electrolytes with the first goal of prevention and treatment of dehydration. The symptomatic relief is provided by Anti-motility agents. The most common treatments include bismuth subsalicylate and Synthetic opiates such as loperamide and diphenoxylate that can reduce frequency of bowel movements and therefore enable travelers to ride on an airplane or bus. The symptomatic treatment is followed by antimicrobial strategies including antibiotics. Antibiotic therapy is recommended either with or without loperamide for travelers with moderate to severe symptoms (three or more unformed stools during an 8-h period, particularly if associated with nausea, vomiting, abdominal cramping, fever, or bloody stools). Marketed drugs for traveler’s diarrhea include Aemcolo (rifamycin, Cosmo Pharmaceuticals), Xifaxan (rifaximin, Salix Pharmaceuticals). Detailed chapters for all of these drugs, as well as another promising candidates have been covered in the report.
Traveler’s Diarrhea (TD) Market Outlook
The Traveler’s Diarrhea (TD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Traveler’s Diarrhea (TD) was estimated to be USD 385.07 million in 2018. The United States accounts for the largest market size of Traveler’s Diarrhea, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Currently, includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.
To meet the increasing demand for the treatment of Traveler’s Diarrhea (TD), companies have shifted their focus towards the development of targeted therapies. Expected launch of potential targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma, may increase the market size in the coming years, assisted by an increase in the incident population of Traveler’s Diarrhea (TD) & awareness of the disease.
Traveler’s Diarrhea (TD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Traveler’s Diarrhea market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Key players are working robustly on new therapies with novel mechanism of action, including Ivosidenib (Agios Pharmaceuticals), Pemigatinib (Incyte Corporation), Infigratinib (QED Therapeutics), Melphalan Hydrochloride (Delcath Systems), Regorafenib (Bayer), Larotrectinib (Loxo Oncology), Entrectinib (Hoffmann-La Roche), Derazantinib (Basilea Pharmaceutica) and Erdafitinib(Janssen Research & Development).
Traveler’s Diarrhea (TD) Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Traveler’s Diarrhea (TD) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Traveler’s Diarrhea (TD) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Traveler’s Diarrhea (TD) market.
• Organize sales and marketing efforts by identifying the best opportunities for Traveler’s Diarrhea (TD) market.
• To understand the future market competition in the Traveler’s Diarrhea (TD) market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook